Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesEffects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach
Gender Medicine, 08/17/09
Ferris S et al. – In these patients with MCI, a significant decrease in the risk for progression to AD was found with rivastigmine over 3 to 4 years. The proportion of women whose disease progressed to AD was significantly lower in the rivastigmine group than the placebo group. This effect was not found in men. These data suggest that prospectively adjusting for predictive factors could lead to a more accurate estimation of treatment benefits in future studies of MCI.
Related Articles
Safety/Tolerability and Efficacy of Rivastigmine in Taiwanese Patients with Alzheimer's Disease: A Prospective Post-Marketing Surveillance Study
Clinical Drug Investigation, 10/14/09
Relevance Score: 87%
Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence
Dementia and Geriatric Cognitive Disorders, 11/10/09
Relevance Score: 83%
Today in Dementia...keeping you current
Receive free subspecialty "5-minute updates" via email
Behavioural and psychological symptoms in vascular dementia; differences between small and large vessel disease
Journal of Neurology, Neurosurgery, and Psychiatry , 12/11/09
Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/11/09
Disturbances in Everyday Life Activities and Sequence Disabilities in Tool use for Alzheimer Disease and Vascular Dementia
Cognitive and Behavioral Neurology, 12/11/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/11/09
Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/11/09
Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09
Sponsor
Article Search
Sponsor
Sponsor